Sign in

    Paul Mattis

    Research Analyst at Stifel

    Paul Matteis is Managing Director and Head of Biotech Research at Stifel, specializing in therapeutics with in-depth coverage of biotechnology companies, particularly in neuroscience, central nervous system, and rare diseases. He has led research on a range of small- and mid-cap biotech firms, previously serving as Senior Biotechnology Analyst at Leerink and as a research assistant at the Harvard Division of Sleep Medicine. Named 'Runner Up' in Small/Mid Cap Biotechnology by Institutional Investor from 2019 to 2024 and a 'Rising Star' in 2015 and 2016, Matteis has earned recognition for his analytical insight and sector expertise. He joined Stifel in 2018 after graduating Phi Beta Kappa from Skidmore College, where he studied Psychology and Pre-Medical Sciences.

    Paul Mattis's questions to ACADIA PHARMACEUTICALS (ACAD) leadership

    Paul Mattis's questions to ACADIA PHARMACEUTICALS (ACAD) leadership • Q3 2024

    Question

    An analyst on behalf of Paul Mattis of Stifel asked about the expected return on investment (ROI) for the NUPLAZID direct-to-consumer (DTC) campaign in 2025, given the strong execution in 2024.

    Answer

    Executive Brendan Teehan stated that since the campaign began in mid-August, the vast majority of its benefits will be realized starting in 2025. He emphasized that the lifetime value of a NUPLAZID patient extends beyond 2025, so the full ROI will not be realized in a single year. While enthusiastic about early indicators like website visits, the primary impact on new patient starts and their continuing value will be seen in 2025 and beyond.

    Ask Fintool Equity Research AI